Related Experiment Video
Updated: Sep 1, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.6K
ALPELISIB - INDUCED HYPERGLYCEMIA
P S Ekanayake1,2, J Gerwer1,2, K Mccowen1
1University of California San Diego - Division of Endocrinology, Diabetes and Metabolism, La Jolla, California, United States.
Acta Endocrinologica (Bucharest, Romania : 2005)
|August 17, 2022
Summary
New PI3K inhibitors like alpelisib can cause severe hyperglycemia in breast cancer patients. This on-target side effect requires careful management, as insulin therapy may be needed to control blood glucose levels.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Phosphoinositide-3-kinase (PI3K) pathway inhibitors are emerging as targeted therapies for various malignancies.
- Hyperglycemia is a known on-target side effect of PI3K inhibitors due to their role in insulin signaling.
Observation:
- This case series examines three women with HR+, Her2- PI3K-mutated breast cancer who developed severe hyperglycemia after starting alpelisib.
- The hyperglycemia was noted to be new onset and severe in all three patients.
- In one case, hyperglycemia resolved within a week of discontinuing alpelisib.
Findings:
- Alpelisib, a PI3K inhibitor, can induce significant hyperglycemia, even in patients without pre-existing diabetes.
- The severity of hyperglycemia may necessitate treatment interruption or dose adjustment.
- Management strategies for PI3K inhibitor-induced hyperglycemia are still being established.
Implications:
- Understanding the mechanism and management of PI3K inhibitor-induced hyperglycemia is crucial for optimizing cancer treatment.
- Further research is needed to clarify the optimal glucose-lowering strategies, including the role of exogenous insulin.
- This highlights the importance of close monitoring for metabolic side effects in patients receiving PI3K pathway inhibitors.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
239
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
239
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
275
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
275
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
247
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
247
01:15Hypoglycemia and Glucagon
318
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
318
01:06Oral Hypoglycemic Agents: Glinides
241
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
241
01:24Glucagon-like Receptor Agonists
400
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
400